<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534558</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 102-5462B</org_study_id>
    <secondary_id>ChangGungMH</secondary_id>
    <nct_id>NCT02534558</nct_id>
  </id_info>
  <brief_title>Pathomechanism of MicroRNA-29 in Shoulder Stiffness</brief_title>
  <official_title>Pathomechanism of MicroRNA-29 in Shoulder Stiffness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The team integrates experimental analyses of clinical and basic medicine and transgenic mice
      models. miR-29a acts a potent protective factor against excessive fibrosis in myofibroblasts
      of subacromial bursa tissue. Gain of miR-29a stabilizes tendon and synovial tissue
      homeostasis that alleviates tissue stiffness and maintains function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims of first: The team will evaluate the associations among the mR-29a, miR-29b, miR-29c
      expression in subacromial bursa and subacromial fluid, incidence of shoulder stiffness,
      Constant scores, and VAS.

      Aims of second: The team will isolate primary myofibroblast from subacromial bursa tissue as
      in vitro models and investigate the molecular events in the IL-1β modulation of miR-29a
      expression and the molecular mechanism underlying miR-29a inhibition of fibrotic matrix
      accumulation and apoptotic reactions in myofibroblast cultures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2014</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The microRNA expression, mRNA expression as a measure</measure>
    <time_frame>48hr</time_frame>
    <description>Differences among incidence, microRNA expression, mRNA expression of shoulder stiffness are analyzed using non-parametric student's t-test. P value of &lt; 0.05 is considered statistically significant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stiffness of Shoulder, Not Elsewhere Classified</condition>
  <arm_group>
    <arm_group_label>miR-29a precursor oligonucleotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>miR-29a antisense oligonucleotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>miR 29a</intervention_name>
    <description>Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified</description>
    <arm_group_label>miR-29a precursor oligonucleotide</arm_group_label>
    <arm_group_label>miR-29a antisense oligonucleotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18 to 80 years

          -  receiving surgery for open acromioplasty

        Exclusion Criteria:

          -  shoulder disorders caused by traumatic fracture

          -  previous surgery

          -  osteoarthritis

          -  malignant disorders

          -  hepatic disorders

          -  renal disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang-Jih Ko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jih-Yang Ko, MD</last_name>
    <phone>886-7-731-7123</phone>
    <phone_ext>8003</phone_ext>
    <email>kojy@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung city</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jih-Yang Ko, MD</last_name>
      <phone>886-7-731-7123</phone>
      <phone_ext>8003</phone_ext>
      <email>kojy@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Jih-Yang Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MicroRNA-29</keyword>
  <keyword>shoulder stiffness</keyword>
  <keyword>mir-29a</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

